BioStock: BioInvent deepens collaboration with MSD

BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination with MSD’s Keytruda in the second part of a phase I/IIa study in solid tumours. The monotherapy part of the study has been ongoing since December, and the first results are expected by year-end 2024.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/bioinvent-deepens-collaboration-with-msd/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/